Cloning and expression of in vivo refolded antibody fragment
AssigneeCouncil of Scientific and Industrial Research
InventorsRahul Sharad BHAMBURE, Aatir Asad TUNGEKAR
Life of this patent
Estimating the term…
Abstract
The present invention relates to a process for production and recovery of in-vivo refolded recombinant antibody fragment in a soluble form in the cytoplasm of a microbial expression system. More particularly, the present invention relates to a process for production of in-vivo refolded recombinant humanized biosimilar Ranibizumab antibody fragment in a soluble form in the cytoplasm of a microbial expression system. The present process provides an increased yield of the recombinant Ranibizumab accompanied with a reduction in overall manufacturing time for the production of rHu Ranibizumab in its native form to three days.
Claims11
A process for expression and recovery of an in-vivo refolded recombinant antibody fragment in a soluble form comprising;
- a. providing a microbial host cell overexpressing disulfide isomerase with non-expression of enzymes for reducing ability of cytoplasm, said cell comprising a DNA construct encoding light and heavy chain of a recombinant antibody fragment;
- b. culturing said microbial host cell of step (a) in a complex nutrient medium comprising glycerol at 30° C., pH 7 to obtain a culture;
- c. reducing temperature of the culture and adding IPTG to said culture to induce expression to obtain a culture broth comprising in-vivo refolded recombinant antibody fragment;
- d. centrifuging the culture broth of step (c) to obtain a cell mass;
- e. disrupting the cell mass of step (d) to obtain a cell lysate;
- f. centrifuging the cell lysate of step (e) to obtain a first supernatant;
- g. precipitating the first supernatant of step (f) at pH 4.0 followed by centrifugation to obtain a second supernatant;
- h. subjecting the second supernatant of step (g) to ultrafiltration to obtain the in-vivo refolded recombinant antibody fragment in a retentate fraction;
- i. subjecting said retentate fraction of step (h) to a multimodal chromatography and an affinity chromatography to obtain the purified in-vivo refolded recombinant antibody fragment in a soluble form.
Dependencies are inferred from the claim text.